Yangtze River Pharmaceutical Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yangtze River Pharmaceutical Group
One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.
AbbVie claims a former employee took Humira manufacturing process know-how to Alvotech. Settlement is likely as Alvotech does not want to delay development of its biosimilar and AbbVie doses not want to disclose its trade secrets in court.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.